Market Overview

XenoPort May Be Beneficiary of Biogen Patent Filings

Related BIIB
2 Columbia Growth Funds Notch Impressive Three-Month Performance
Biogen Idec, Inc. Suddenly Struggling To Keep Up With The Biotech Joneses
Don't Panic Over Recent Tech Turmoil (Fox Business)
Related XNPT
XenoPort's XP23829 in Phase II Study - Analyst Blog
Xenoport, Inc. (XNPT) Soars: Stock Up 5.9% - Tale of the Tape

Brian Abrahams, a Wells Fargo analyst, believes that Biogen (NASDAQ: BIIB) MS pill patents will be a positive boost for XenoPort (NASDAQ: XNPT).

Further patent applications could provide patent protection until 2032 for Biogen's BG-12, which should benefit XenoPort's '829 drug, an earlier stage derivative of BG-12, with added protection from generic competition.

BIIB is currently up 1.5 percent in pre-market trading, while XNPT is currently unchanged.

Latest Ratings for BIIB

DateFirmActionFromTo
Jul 2014Credit SuisseMaintainsOutperform
Jul 2014Deutsche BankMaintainsBuy
Jul 2014JefferiesMaintainsBuy

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Analyst Ratings

 

Related Articles (BIIB + XNPT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters